Toggle light / dark theme

Brain stimulation poised to move from last resort to frontline treatment

Get alerts for new articles, or get an alert when an article is cited.

Manage alerts

Even so, proponents say that TMS and other noninvasive brain-stimulation methods—which include updated forms of electroconvulsive therapy (ECT) and transcranial direct-current stimulation—have yet to achieve their full potential, both as research tools and as clinical treatments for a range of neurological conditions. To get there, researchers want to fully understand the biological mechanisms behind these techniques, along with finding more rigorous ways to test them in the lab, all with a view toward making treatments more tailored and reliably successful. With its demonstrated benefits and lack of serious side effects, Colleen Loo, a neurostimulation pioneer at the University of New South Wales, says, “there’s no reason TMS can’t be used as a frontline treatment” for major depression.

A Randomized, Controlled Clinical Trial Demonstrates Improved Cognitive Function in Senior Dogs Supplemented with a Senolytic and NAD+ Precursor Combination

Aging reversed in dogs face_with_colon_three


Age-related decline in mobility and cognition are associated with cellular senescence and NAD+ depletion in dogs and people. A combination of a novel NAD+ precursor and senolytic, LY-D6/2 was examined in this randomized controlled trial. Seventy dogs were enrolled and allocated into placebo, low or full dose groups. Primary outcomes were change in cognitive impairment measured with the owner-reported Canine Cognitive Dysfunction Rating (CCDR) scale and change in activity measured with physical activity monitors. Fifty-nine dogs completed evaluations at the three-month primary endpoint, and 51 reached the six-month secondary endpoint. There was a significant difference in CCDR score across treatment groups from baseline to the primary endpoint (p=0.02) with the largest decrease in the full dose group. There were no significant differences between groups in changes in measured activity. However, the proportion of dogs that improved in frailty and owner-reported activity levels and happiness was higher in the full dose group than other groups. Adverse events occurred equally across groups. All groups showed improvement in cognition, frailty, and activity suggesting placebo effect and benefits of trial participation. We conclude that LY-D6/2 significantly improves owner-assessed cognitive function and may have broader effects on frailty, activity and happiness as reported by owners.

The authors have declared no competing interest.

Insomnia: Insomnia is a common sleep disorder

Insomnia is a common sleep disorder. If you have it, you may have trouble falling asleep, staying asleep, or both. As a result, you may get too little sleep or have poor-quality sleep. You may not feel refreshed when you wake up.

What are the types of insomnia?

Insomnia can be acute (short-term) or chronic (ongoing). Acute insomnia is common. Common causes include stress at work, family pressures, or a traumatic event. It usually lasts for days or weeks.

‘Can control computer mouse with thoughts’: Says Elon Musk on Neuralink’s first human patient as he successfully recovers

Elon Musk disclosed that a human patient implanted with a brain chip from the company has fully recovered and demonstrated the ability to control a computer mouse using their thoughts.

Alzheimer’s Might Not Actually Be a Brain Disease, Expert Reveals

The pursuit of a cure for Alzheimer’s disease is becoming an increasingly competitive and contentious quest with recent years witnessing several important controversies.

In July 2022, Science magazine reported that a key 2006 research paper, published in the prestigious journal Nature, which identified a subtype of brain protein called beta-amyloid as the cause of Alzheimer’s, may have been based on fabricated data.

One year earlier, in June 2021, the US Food and Drug Administration had approved aducanumab, an antibody-targeting beta-amyloid, as a treatment for Alzheimer’s, even though the data supporting its use were incomplete and contradictory.

Korean researchers develop insect brain-inspired motion detector

The new semiconductor is expected to have some important applications in things like transportation and security systems in both industry and the public.

Korean researchers have developed a new “intelligent sensor” semiconductor that works similarly to the optic nerves of insects.


A team of researchers from Korea have developed an insect brain-inspired semiconductor that can be used as a fast, low power motion detector.